See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.
There is no publicly available rating for this medical professional for one of the following reasons:
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
My clinical expertise is in Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis.
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Research in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease. Active research projects in my laboratory include:1) Developing chimeric antigen receptors (CARs) for adoptive immunotherapy of cancer with enhanced function and improved safety.2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.
Philipson Benjamin I, O'Connor Roddy S, May Michael J, June Carl H, Albelda Steven M, Milone Michael C: 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Science signaling 13 (625): 2020.
Sellmyer Mark A, Richman Sarah A, Lohith Katheryn, Hou Catherine, Weng Chi-Chang, Mach Robert H, O'Connor Roddy S, Milone Michael C, Farwell Michael D: Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. Molecular therapy : the journal of the American Society of Gene Therapy 28 (1): 42-51,2020.
O'Connor Roddy S, Milone Michael C: Testing the Specificity of Compounds Designed to Inhibit CPT1A in T Cells. Methods in molecular biology (Clifton, N.J.) 2097 : 83-90,2020.
Ghassemi Saba, Milone Michael C: Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy. Journal of visualized experiments : JoVE (154): 2019.
Sheng Feng, Milone Michael C: Commentary. Clinical chemistry 65 (11): 1361,2019.
Garfall Alfred L, Dancy Ehren K, Cohen Adam D, Hwang Wei-Ting, Fraietta Joseph A, Davis Megan M, Levine Bruce L, Siegel Don L, Stadtmauer Edward A, Vogl Dan T, Waxman Adam, Rapoport Aaron P, Milone Michael C, June Carl H, Melenhorst J Joseph: T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood advances 3 (19): 2812-2815,2019.
Feins Steven, Kong Weimin, Williams Erik F, Milone Michael C, Fraietta Joseph A: An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. American journal of hematology 94 (S1): S3-S9,2019.
Thibodeaux Suzanne R, Milone Michael C: Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. Clinical chemistry 65 (4): 519-529,2019.
Cohen Adam D, Garfall Alfred L, Stadtmauer Edward A, Melenhorst J Joseph, Lacey Simon F, Lancaster Eric, Vogl Dan T, Weiss Brendan M, Dengel Karen, Nelson Annemarie, Plesa Gabriela, Chen Fang, Davis Megan M, Hwang Wei-Ting, Young Regina M, Brogdon Jennifer L, Isaacs Randi, Pruteanu-Malinici Iulian, Siegel Don L, Levine Bruce L, June Carl H, Milone Michael C: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of clinical investigation 130 : 2210-2221,2019.
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 4 (4): pii: 127684,2019.
3400 Spruce Street 7103 Founders Pavilion